Suprafascial Vancomycin Powder for Prevention of Surgical Site Infections After Instrumented Posterior Spinal Fusion
Status:
Recruiting
Trial end date:
2023-03-31
Target enrollment:
Participant gender:
Summary
Surgical site infections (SSI) after spine surgery may occur in up to 12% of cases and can
lead to increased morbidity, and healthcare costs In this randomized controlled trial the
investigators aim to prospectively investigate the efficacy and safety of suprafascial
intrawound vancomycin powder in reducing the rate of SSIs after instrumented spinal fusion
surgery. Secondary aims of the study are the incidence of vancomycin-related complications,
vancomycin-resistant bacterial infections in the treatment arm as well as the rate of
revision surgeries due to SSIs.